The BD Director of a French CRO that "provides preclinical in vivo and ex vivo CRO services with 20 years of expertise in evaluating drugs targeting metabolic disorders such as obesity, diabetes, NASH/MASH, fibrosis, diabetic nephropathy, cardiovascular complications, dyslipidemia and atherosclerosis" has no business following an Australian oncology drug development biotech".
Unless of course that company is looking for services and expertise in evaluating drugs targeting metabolic disorders...
Oh, by the way:
RAC Price at posting:
$1.24 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)